Login Register Cart 0
Generic placeholder image

Current Respiratory Medicine Reviews

Editor-in-Chief

ISSN (Print): 1573-398X
ISSN (Online): 1875-6387

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

A Case Report of Chronic Inflammatory Demyelinating Polyneuropathy following COVID-19 Vaccination

Author(s): Hedyieh Karbasforooshan, Shahram Amini, Reza Boostani, Pourandokht Mousavian and Hesamoddin Hosseinjani*

Volume 20, Issue 1, 2024

Published on: 25 January, 2024

Page: [79 - 83] Pages: 5

DOI: 10.2174/011573398X278492231228094147

Price: $65

Abstract

Introduction: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a peripheral polyneuropathy. Chronic damage to neuronal myelin by the immune system results in inflammation and demyelination of the peripheral nervous system. Several side effects have been reported with Coronavirus disease 2019 (COVID-19) vaccines. There are some reports of vaccineinduced- CIDP. In this study, we described the occurrence of CIDP in a patient with a history of receiving the first dose of a COVID-19 vaccine, Sputnik V.

Case Report: We presented a patient receiving the COVID-19 vaccine Sputnik V two weeks before progressive flaccid tetraparesis and dysautonomia. He was first diagnosed with Guillain- Barre Syndrome (GBS). Two episodes of worsening the weakness occurred within 8 weeks from the onset of the disease, and the treatment was repeated as GBS-Treatment-related Fluctuations (TRF) and relapse. Also, a few relapses happened eight weeks after the disease's onset. Hence, he was diagnosed with “acute-onset CIDP”. The patient received several intravenous immunoglobulin (IVIG) courses as maintenance therapy. No further deterioration was reported during the follow-up.

Conclusion: Post-vaccination GBS is a known phenomenon. However, there are several reports of vaccine-induced-CIDP. This is the first reported case of acute-onset CIDP associated with the Sputnik V vaccine in Iran. Subsequent studies are required to determine the definite relationship between COVID-19 vaccination and CIDP.

« Previous
Graphical Abstract

[1]
Broers MC, Bunschoten C, Nieboer D, Lingsma HF, Jacobs BC. Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: A systematic review and meta-analysis. Neuroepidemiology 2019; 52(3-4): 161-72.
[http://dx.doi.org/10.1159/000494291] [PMID: 30669140]
[2]
Kamil K, Yazid MD, Idrus RBH, Das S, Kumar J. Peripheral demyelinating diseases: From biology to translational medicine. Front Neurol 2019; 10: 87.
[http://dx.doi.org/10.3389/fneur.2019.00087] [PMID: 30941082]
[3]
Peltier AC, Donofrio PD. Chronic inflammatory demyelinating polyradiculoneuropathy: From bench to bedside.Seminars in neurology. Thieme Medical Publishers 2012.
[4]
Brostoff JM, Beitverda Y, Birns J. Post-influenza vaccine chronic inflammatory demyelinating polyneruopathy. Age Ageing 2008; 37(2): 229-30.
[http://dx.doi.org/10.1093/ageing/afm151] [PMID: 17993473]
[5]
Kelkar P. Chronic inflammatory demyelinating polyneuropathy (CIDP) with rapid progression after influenza vaccination: A report of three cases. J Clin Neuromuscul Dis 2006; 8(1): 20-5.
[http://dx.doi.org/10.1097/01.cnd.0000245215.86174.79]
[6]
Remiche G, Abramowicz M, Mavroudakis N. Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) associated to hereditary neuropathy with liability to pressure palsies (HNPP) and revealed after influenza AH1N1 vaccination. Acta Neurol Belg 2013; 113(4): 519-22.
[http://dx.doi.org/10.1007/s13760-013-0255-x] [PMID: 24146347]
[7]
Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med 2021; 27(2): 205-11.
[http://dx.doi.org/10.1038/s41591-021-01230-y] [PMID: 33469205]
[8]
Aksu SB, Öztürk GZ. A rare case of shingles after COVID-19 vaccine: Is it a possible adverse effect? Clin Exp Vaccine Res 2021; 10(2): 198-201.
[http://dx.doi.org/10.7774/cevr.2021.10.2.198] [PMID: 34222134]
[9]
Hasan T, Khan M, Khan F, Hamza G. Case of Guillain-Barré syndrome following COVID-19 vaccine. BMJ Case Rep 2021; 14(6): e243629.
[http://dx.doi.org/10.1136/bcr-2021-243629] [PMID: 34187803]
[10]
Maramattom BV, Krishnan P, Paul R, et al. Guillain-Barré syndrome following ChAdOx1-S/nCoV-19 vaccine. Ann Neurol 2021; 90(2): 312-4.
[http://dx.doi.org/10.1002/ana.26143] [PMID: 34114256]
[11]
Abu-Rumeileh S, Garibashvili T, Ruf W, et al. Exacerbation of chronic inflammatory demyelinating polyneuropathy in concomitance with COVID-19. J Neurol Sci 2020; 418: 117106.
[http://dx.doi.org/10.1016/j.jns.2020.117106] [PMID: 32911389]
[12]
Van Looy E, Veenker L, Steyaert A, Leenders J, Malfroid G, De Cauwer H. COVID-19-induced exacerbation of chronic inflammatory demyelinating polyneuropathy. J Neurol 2021; 268(9): 3129-31.
[http://dx.doi.org/10.1007/s00415-021-10417-9] [PMID: 33606069]
[13]
Ginanneschi F, Vinciguerra C, Volpi N, Piscosquito G, Barone P, Rossi A. Chronic inflammatory demyelinating polyneuropathy after SARS-CoV2 vaccination: Update of the literature and patient characterization. Immunol Res 2023; 71(6): 833-8.
[http://dx.doi.org/10.1007/s12026-023-09406-z] [PMID: 37395901]
[14]
Katada E, Toyoda T, Yamada G, Morishima A, Matsukawa N. A case of chronic inflammatory demyelinating polyneuropathy following COVID -19 vaccine. Neurol Clin Neurosci 2022; 10(4): 223-5.
[http://dx.doi.org/10.1111/ncn3.12604] [PMID: 35601443]
[15]
Kaur U, Bala S, Joshi A, et al. Persistent health issues, adverse events, and effectiveness of vaccines during the second wave of COVID-19: A cohort study from a tertiary hospital in north India. Vaccines 2022; 10(7): 1153.
[http://dx.doi.org/10.3390/vaccines10071153] [PMID: 35891317]
[16]
Chakrabarti SS, Tiwari A, Jaiswal S, et al. Rapidly progressive dementia with asymmetric rigidity following ChAdOx1 nCoV-19 vaccination. Aging Dis 2022; 13(3): 633-6.
[http://dx.doi.org/10.14336/AD.2021.1102] [PMID: 35656106]
[17]
Ruts L, Drenthen J, Jacobs BC, van Doorn PA. Distinguishing acute-onset CIDP from fluctuating Guillain-Barré syndrome. Neurology 2010; 74(21): 1680-6.
[http://dx.doi.org/10.1212/WNL.0b013e3181e07d14] [PMID: 20427754]
[18]
Kubota T, Shijo T, Ikeda K, et al. Distal chronic inflammatory demyelinating polyneuropathy following COVID-19 vaccination in a patient with solitary plasmacytoma: A case report and literature review. Intern Med 2023; 62(16): 2419-25.
[http://dx.doi.org/10.2169/internalmedicine.1365-22] [PMID: 37587059]
[19]
Kim S, Lee EK, Sohn E. Two case reports of chronic inflammatory demyelinating polyneuropathy after COVID-19 vaccination. J Korean Med Sci 2023; 38(8): e57.
[http://dx.doi.org/10.3346/jkms.2023.38.e57] [PMID: 36852853]
[20]
Bagella CF, Corda DG, Zara P, et al. Chronic inflammatory demyelinating polyneuropathy after ChAdOx1 nCoV-19 vaccination. Vaccines 2021; 9(12): 1502.
[http://dx.doi.org/10.3390/vaccines9121502] [PMID: 34960248]
[21]
de Souza A, Oo WM, Giri P. Inflammatory demyelinating polyneuropathy after the ChAdOx1 nCoV-19 vaccine may follow a chronic course. J Neurol Sci 2022; 436: 120231.
[http://dx.doi.org/10.1016/j.jns.2022.120231] [PMID: 35313224]
[22]
Suri V, Pandey S, Singh J, Jena A. Acute-onset chronic inflammatory demyelinating polyneuropathy after COVID-19 infection and subsequent ChAdOx1 nCoV-19 vaccination. BMJ Case Rep 2021; 14(10): e245816.
[http://dx.doi.org/10.1136/bcr-2021-245816] [PMID: 34607818]
[23]
Abo-Zed A, Pinevich A. Guillain-Barré syndrome, or acute on chronic inflammatory demyelinating polyneuropathy, following Moderna COVID-19 vaccine. Chest 2021; 160(4): A898.
[http://dx.doi.org/10.1016/j.chest.2021.07.838]
[24]
Angeli F, Reboldi G, Trapasso M, Santilli G, Zappa M, Verdecchia P. Blood pressure increase following COVID-19 vaccination: A systematic overview and meta-analysis. J Cardiovasc Dev Dis 2022; 9(5): 150.
[http://dx.doi.org/10.3390/jcdd9050150] [PMID: 35621861]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy